Global Study Reveals WHO-Recommended Antibiotics Fail in 75 Percent of Neonatal Sepsis Cases in Developing Nations

WHO-recommended sepsis antibiotics for newborns are effective in only 25% of cases in LMICs due to rising AMR. Learn why local treatment strategies are vital.

By: AXL Media

Published: Apr 21, 2026, 4:46 AM EDT

Source: Information for this report was sourced from European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

The Failure of Universal Antibiotic Guidelines

Neonatal sepsis remains one of the leading causes of newborn mortality globally, yet the standard medical response is currently failing in the regions where it is needed most. For decades, the World Health Organization (WHO) has recommended a combination of ampicillin and gentamicin as the first-line empirical treatment for suspected infections in newborns. However, new data from the BARNARDS II study indicates that this "one-size-fits-all" approach is effective in only 25 percent of cases in low- and middle-income countries (LMICs). This discrepancy stems from the fact that global recommendations are largely based on data from high-income settings, failing to account for the highly resistant pathogens prevalent in South Asia and Africa.

Antimicrobial Resistance and Pathogen Profiling

Between February 2024 and October 2025, researchers from the University of Oxford tracked over 14,000 neonates across 13 tertiary units in Pakistan, Bangladesh, and Nigeria. Among the 2,821 cases with confirmed pathogen and susceptibility data, the levels of antimicrobial resistance (AMR) were described as "concerning" by the research team. The study found that local clinicians have already begun deviating from WHO guidelines out of necessity, frequently opting for amikacin and cefotaxime instead. This deviation is not a sign of poor adherence but rather a clinical adaptation to a reality where traditional first-line drugs offer almost no protection against local bacteria and fungi.

Clinical Vulnerability and Mortality Rates

The impact of receiving inappropriate initial antibiotic therapy is severe. Unadjusted analysis showed that neonates who were given antibiotics that the identified pathogen was resistant to faced a 32.1 percent mortality rate, nearly double the 17.9 percent rate seen in those who received appropriate therapy. Lead author Dr. Kathryn Thomson noted that while gestational age remains the strongest predictor of mortality due to the underlying vulnerability of the infants, the choice of antibiotic remains a critical factor in the speed and success of recovery. Prompt, effective therapy is the only way to counteract the rapid progression of sepsis in the first month of life.